Additional sensitivity analyses
| MM | TAVI | Incremental values | |||||
|---|---|---|---|---|---|---|---|
| Parameter | Costs | Benefits | Costs | Benefits | Costs | Benefits | ICER* |
| Analysis: fixed rather than time-dependent hospitalisation rates | |||||||
| ADVANCE high risk vs all PARTNER-B | £14 101 (£11 990, £16 271) | 0.78 (0.74, 0.82) | £37 261 (£32 388, £42 279) | 2.02 (1.87, 2.17) | £23 160 | 1.25 | £18 577 |
| All ADVANCE vs all PARTNER-B | £14 149 (£11 915, £16 394) | 0.78 (0.74, 0.82) | £36 763 (£32 167, £42 322) | 2.29 (2.20, 2.36) | £22 614 | 1.51 | £14 978 |
| Analysis: fixed utility decrements rather than time-dependent utility | |||||||
| ADVANCE high risk vs all PARTNER-B | £13 153 (£11 287, £15 211) | 0.78 (0.74, 0.82) | £35 161 (£30 803, £40 085) | 2.11 (1.94, 2.26) | £22 009 | 1.33 | £16 527 |
| All ADVANCE vs all PARTNER-B | £13 091 (£11 205, £15 243) | 0.78 (0.74, 0.82) | £34 241 (£29 985, £39 271) | 2.39 (2.29, 2.48) | £21 150 | 1.61 | £13 121 |
| Analysis: removal of death cost | |||||||
| ADVANCE high risk vs all PARTNER-B | £9688 (£8424, £11 007) | 0.78 (0.74, 0.82) | £33 898 (£29 392, £39 217) | 2.02 (1.86, 2.16) | £24 210 | 1.24 | £19 481 |
| All ADVANCE vs all PARTNER-B | £9674 (£8409, £11 107) | 0.78 (0.74, 0.82) | £33 289 (£28 861, £39 037) | 2.29 (2.20, 2.37) | £23 614 | 1.51 | £15 613 |
| Analysis: Use of a common HF hospitalisation cost for TAVI as well as MM | |||||||
| ADVANCE high risk vs all PARTNER-B | £11 706 (£10 193, £13 171) | 0.78 (0.74, 0.82) | £35 101 (£30 797, £40 163) | 2.02 (1.86, 2.16) | £23 394 | 1.24 | £18 883 |
| All ADVANCE vs all PARTNER-B | £11 659 (£10 303, £13 092) | 0.78 (0.74, 0.82) | £34 385 (£29 889, £39 992) | 2.29 (2.20, 2.37) | £22 726 | 1.51 | £15 023 |
Data presented as mean, 95% CrI. Time horizon=5 years.
*All values to be interpreted as £ per QALY gained.
CrI, credible interval; ICER, incremental cost-effectiveness ratio; MM, medical management; QALY, quality-adjusted life-years; TAVI, transcatheter aortic valve implantation.